661
Participants
Start Date
August 7, 2019
Primary Completion Date
December 14, 2021
Study Completion Date
December 14, 2021
Cefepime/VNRX-5133 (taniborbactam)
Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
Meropenem
Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
Site 160410, Lima
Site 160406, Lima
Site 160403, Cuzco
Site 134801, Budapest
Site 110010, Sofia
Site 110004, Sofia
Site 110005, Sofia
Site 110008, Sofia
Site 110007, Plovdiv
Site 134803, Nyíregyháza
Site 110001, Veliko Tarnovo
Site 110009, Gabrovo
Site 110002, Pleven
Site 180402, Kharkiv
Site 134804, Szeged
Site 110003, Rousse
Site 119101, Zagreb
Site 119106, Zagreb
Site 189001, Belgrade
Site 189002, Belgrade
Site 119103, Split
Site 180403, Vinnytsia
Site 179204, Diyarbakır
Site 148402, Colima
Site 179203, Bornova
Site 180401, Lutsk
Site 148401, Guadalajara
Site 180404, Dnipro
Site 179207, Adapazarı
Site 179202, Bostancı
Site 180407, Zaporizhzhya
Site 180408, Ivano-Frankivsk
Site 184003, Buena Park
184012, Northridge
Site 184002, Chula Vista
Site 184001, La Mesa
Site 156002, Beijing
Site 156006, Beijing
Site 156004, Dalian
Site 164307, Moscow
Site 156005, Nanjing
Site 164303, Saint Petersburg
Site 156017, Shanghai
Site 164201, Craiova
Site 156008, Nanjing
Site 156007, Nanjing
Site 156028, Shandong
Site 156020, Tianjin
Site 156013, Ningbo
Site 156003, Nanchang
Site 164311, Rostov-on-Don
Site 164308, Pyatigorsk
Site 156010, Xiamen
Site 156030, Fujian
Site 156011, Chongqing
Site 156012, Chongqing
Site 164302, Saratov
Site 164301, Penza
Site 156025, Guangzhou
Site 156014, Guangdong
Site 156027, Guangdong
Site 156018, Guiyang
Site 156015, Chendu
Site 156029, Ürümqi
Site 103203, Córdoba
Site 107601, Belo Horizonte
Site 107608, São Paulo
Site 156022, Baotou
Site 156016, Shijiazhuang
Site 142803, Daugavpils
Site 142804, Riga
Site 142801, Riga
Site 160404, Trujillo
Site 164206, Bucharest
Site 164205, Bucharest
Site 164204, Bucharest
Site 179205, Çankaya
Site 180406, Kyiv
Venatorx Pharmaceuticals, Inc.
INDUSTRY